2. Shuangcheng Pharmaceutical (002693): The company's net profit in 2020 was-53.33 million yuan, up -3 16.29% year-on-year. The company is a leading enterprise in peptide drugs and one of the key enterprises in the domestic chemical peptide synthesis industry. Its main products include thymosin for injection, somatostatin for injection and thymopentin for injection.
3. Changchun High-tech (000661): According to the 2020 annual report, Changchun High-tech achieved a net profit of 3.047 billion yuan, up 7 1.64% year-on-year. Production and sales of biopharmaceuticals and Chinese patent medicines.
4. Shuanglu Pharmaceutical (002038): The 2020 annual report shows that Shuanglu Pharmaceutical achieved a net profit of 365 million yuan, a year-on-year increase of -25.08%.
Shen Lian Bio 688098: Judging from the gross profit rate in the last three years, the average gross profit rate in the last three years was 82.05%, the lowest gross profit rate in the last three years was 20 18 years, 80. 17%, and the highest was 83.69% in 2020.
The company's products are swine foot-and-mouth disease O-type synthetic peptide vaccine (polypeptide 2600+2700+2800) and swine foot-and-mouth disease O-type and A-type bivalent synthetic peptide vaccine (polypeptide 2700+2800+MM 13), which obtained the approval number of veterinary drug products.
Xinbang Pharmaceutical Co., Ltd. 002390: According to the gross profit rate in the past three years, the average gross profit rate in the past three years was 2 1.74%, the lowest gross profit rate in the past three years was 2 1.42% in 2020, and the highest gross profit rate was 20 1% and 20 19 years was 22.0/.
Xinbang Pharmaceutical intends to purchase 0/00% equity of Zhongpeptide Biochemical/KLOC-by issuing shares at a transaction price of 2 billion yuan. China Peptide Biochemistry mainly provides peptide customization services for research and development institutions of new peptide drugs. In 2005, he entered the field of in vitro diagnostic reagents, and developed a variety of drugs and early pregnancy detection reagents certified by FDA and CE. In addition, the company's net profit in the first half of the year increased by 50% to 100%.
Shengnuo Bio-688 1 17: From the perspective of gross profit rate in recent three years, the average gross profit rate in recent three years was 76.56%, the lowest gross profit rate in recent three years was 20 18 years, and the highest was 20 19 years, 80.12.
The company is a high-tech enterprise with polypeptide synthesis and modification as its core technology, with advanced and efficient polypeptide drug process research and development and large-scale production capacity. The company's main business is independent research and development, production and sales of polypeptide raw materials and preparation products with large capacity and strong competitiveness in domestic and foreign markets. At the same time, relying on the technical advantages in the research and development of polypeptide drugs and large-scale production, the company provides innovative polypeptide drug research services, customized polypeptide product production services and polypeptide drug production technology transfer services for domestic and foreign pharmaceutical enterprises.
Nuotai Bio 688076: From the perspective of gross profit rate in recent three years, the average gross profit rate in recent three years is 57.2 1%, the lowest gross profit rate in recent three years is 20 19 years, 53.37%, and the highest is 20 18 years, 60.09%.
The company's main business is independent R&D and customized R&D as well as the production of polypeptide drugs and small molecule drugs.
Saisheng Pharmaceutical Co., Ltd. 300485: Judging from the gross profit rate in the past three years, the average gross profit rate in the past three years was 85.07%, the lowest gross profit rate in the past three years was 83.79% in 2020, and the highest was 86.28% in 20 18 years.
The company is a high-tech enterprise specializing in the research, development, production and sales of biopharmaceuticals (active protease, active polypeptide, active polysaccharide and amphoteric lipid). The research and development direction of products is mainly natural or biotechnology drugs such as cardiovascular and cerebrovascular diseases, immune regulation and nervous system.
Dezhan Health 008 13: From the perspective of gross profit rate in recent three years, the average gross profit rate in recent three years was 8 1. 17%, the lowest gross profit rate in recent three years was 69.63% in 2020, and the highest was 92.63% in 20 18.
In 2020, the company actively promoted the development of new business, and all the products of anti-hangover peptides, raw materials, medical beauty and so on in the biopeptide business sector were listed for sale. Hanting Bio, a holding subsidiary, sells various medical beauty products such as hyaluronic acid essence and polypeptide essence.
Please click to enter the picture description (maximum 18 words).